Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Breast cancer research and treatment - 1 May 2009

Spurdle Amanda B, Deans Andrew J, Duffy David, Goldgar David E, Chen Xiaoqing, Beesley Jonathan, Easton Douglas F, Antoniou Antonis C, Peock Susan, Cook Margaret, Nathanson Katherine L, Domchek Susan M, MacArthur Grant A, Chenevix-Trench Georgia

Abstract excerpt

The p27(kip1) protein functions as an inhibitor of cyclin dependent kinase-2, and shows loss of expression in a large percentage of BRCA1 and BRCA2 breast cancer cases. We investigated the association between CDKN1B gene variants and breast cancer risk in 2359 female BRCA1 and BRCA2 mutation carriers from Australia, the UK, and the USA. Samples were genotyped for five single nucleotide polymorphisms, including...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Cyclin-Dependent Kinase Inhibitor p27

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Genetic Predisposition to Disease

Share to Intracellular Signaling Peptides and Proteins

Share to Polymorphism, Single Nucleotide

Share to Risk Factors

Source

Identifiers

PMID: 18543099
DOI: 10.1007/s10549-008-0083-5

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriers.PMID 18543099Read ↗

Lack of association between cyclin-dependent kinase inhibitor 1B rs2066827 polymorphism and breast cancer susceptibility.Semantic proximity Read ↗

Variant genotypes of CDKN1A and CDKN1B are associated with an increased risk of breast cancer in Chinese women.Semantic proximity Read ↗

CCND1 and CDKN1B polymorphisms and risk of breast cancer.Semantic proximity Read ↗

CDKN1C/p57kip2is a candidate tumor suppressor gene in human breast cancerSemantic proximity Read ↗

Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer.Semantic proximity Read ↗

Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers.Semantic proximity Read ↗

Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases.Semantic proximity Read ↗

Allelic variant at -79 (C>T) in CDKN1B (p27Kip1) confers an increased risk of thyroid cancer and alters mRNA levels.Semantic proximity Read ↗

rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk.Semantic proximity Read ↗

Analysis of cyclin-dependent kinase inhibitor 1B mutation in Han Chinese women with premature ovarian failure.Semantic proximity Read ↗

Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene.Semantic proximity Read ↗

Lack of association between CCND1 G870A polymorphism and the risk of breast and colorectal cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.